63
64
0.8 65
E C E C E E E 1862 6 (20 ) E / 20/200 20/100 20 20 6 3-1 6/60 6 60 0.1 0.1 66
17.5 18.0 6/6 3-1 E C C C 1888 1909 5 0.1 14.5 15.0 C 1.0 0.1 C 3-2 67
3-2 C 68
2. 3-1 3-1 4. 3. 1. E C 2. 3. 1. 2. 1. 1. 2. 3-1 ( ) 69
3-1 1. 2. 3. 3-3 70
C E E 3-4 3-4 1. 1 500-700 2 71
3 0.9 1.0 4 75% 5 2. 1 E 6 C 5 3-5 3-5 2 72
C.L. Contact Lens 3 3-6 3-6 4 0.1 0.8 73
0.5 0.6 0.7 0.6 5 6 0.1 <0.1 0.1 0.1 0.1 3/5 0.1 3/6 E 7 E 8 3-7 74
3-7 E C 3-8 3-8 75
( 3-9) 3-9 1. (1) E / C ( ) (2) E / C (3) E / C 76
(4) (5) ( -0.1 0 1) 2. 1 E / C ( 3-10) 3-10 2 3 E / C 77
4 NTU300 ( 3-11) 3-11 NTU 78
( ) NTU ( ) 参 79
X 3-2 3-2 ( 3-12) 3-3 80
3-12 3-3 1 2 3 4 5 6 7 8 9 10 25 2 5 8 3 9 6 4 58 25 7 9 5 4 5 8 58 500LUX 1 12 9 4 8 81
4 11 12 82
E 0.9 0.9 0.8 0.8 0.9 3-4 3-4 3 4 5 6 7 0.5 0.6 0.7 0.8 0.9 83
( 3-13) 1. 2. 1. 1. 2. 3. 4 3-13 参 84
85
3-14 3-14 86
0.9 0.5 3-15 87
3-15 88
89
3-16 90
91 3-16 参
Atropine 7 14 Cyclopentolate 12 24 tropicamide 4 6 6 15 1. 2. 2-3 92
3. 4. e 2004 5. e 2004 2005 93
94 e 2005 2005 Diopter 2 Spherical equivalent 0.25D 0.25D 0.25D 3.0D 3.0D 6.0D 6.0D 0.25D 2.0D 2.0D 5.0D 5.0D D
3-17 2005 95
200 200 200 500 200 500 0.9 0.5 4~5 0.5 0.6 96
1. 2. 3. 4. 97
3-5 3-5 600 150 300 150 98
1000 200 300 2~3 http://www.vghks.gov.tw/oph/education/amblyopia.htm 99
15 3-18 1. 2. 3. 4. 100
101
2004 3-18 20 102
0. 3 0.05 2000 2003 0.05~ BB 103